SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications. Its lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms tumor 1 (WT1) antigen. The company is also developing SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. SELLAS has a strategic collaboration with Merck & Co., Inc. to evaluate GPS in combination with the PD1 blocker pembrolizumab in a Phase 1/2 clinical trial covering up to five cancer indications, including hematologic malignancies and solid tumors. Additionally, the company has partnerships with GenFleet Therapeutics for GFH009 and Memorial Sloan Kettering Cancer Center for WT1 peptide vaccine technology.

SELLAS Life Sciences Group, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol SLS. The trading currency for its shares is the US Dollar (USD). As a US-based company listed on a major US exchange, its stock is traded in USD, which is standard for companies listed on Nasdaq. Investors should be aware that the company's financial reports and stock price are denominated in US Dollars.

SELLAS Life Sciences Group operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for cancer, leveraging late-stage clinical research to bring new treatments to market. The biotechnology industry is characterized by high research and development costs, long development cycles, and significant regulatory oversight. SELLAS's work in oncology places it at the forefront of developing immunotherapies and targeted small molecule inhibitors for various cancers.

SELLAS Life Sciences Group, Inc. is headquartered in New York, New York, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on the NasdaqCM. Its clinical trials and collaborations, such as the partnership with Merck & Co., Inc., are focused on advancing therapies for cancer patients in the United States. While the company's research and development activities are centered in the US, its therapies, if approved, could potentially be marketed globally, but currently its focus is on the US healthcare market.

SELLAS Life Sciences Group's portfolio includes two main product candidates: galinpepimut-S (GPS) and SLS009 (tambiciclib). GPS is a peptide immunotherapy directed against the Wilms tumor 1 (WT1) antigen, designed to stimulate the immune system to attack cancer cells. SLS009 is a selective small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a role in cancer cell proliferation. Additionally, the company has collaborations for GFH009 (via GenFleet Therapeutics) and WT1 peptide vaccine technology (via Memorial Sloan Kettering Cancer Center). These candidates target a range of hematologic malignancies and solid tumors, with GPS being evaluated in combination with Merck's pembrolizumab in a Phase 1/2 clinical trial.